EGFR mutation + EGFR T790M
|
NSCLC
|
EGFR mutation + EGFR T790M
|
NSCLC
|
osimertinib Resistant: C3 – Early Trials
|
osimertinib Resistant: C3 – Early Trials
|
EGFR mutation + EGFR T790M
|
NSCLC
|
EGFR mutation + EGFR T790M
|
NSCLC
|
osimertinib + afatinib Sensitive: C3 – Early Trials
|
osimertinib + afatinib Sensitive: C3 – Early Trials
|